相关实验视频

Updated: Jul 6, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

治疗风景细胞癌的治疗风景

Yu-Wei Chen¹, Luke Wang², Justine Panian³

¹Division of Hematology Oncology, University of California San Diego, San Diego, CA, USA.

Current treatment options in oncology

|December 28, 2023

概括

细胞癌 (RCC) 的治疗正在通过免疫检查点抑制剂 (ICI) 和立体体辐射疗法 (SBRT) 取得进展. 这些疗法可以改善晚期和高风险RCC患者的生存率,并减少复发.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
免疫治疗是一种免疫疗法.

背景情况:

细胞癌 (RCC) 的治疗环境在过去30年中发生了显著的变化.
已建立的治疗方法包括积极监测,瘤切除和切除性手术.
新兴的疗法正在改变RCC管理.

研究的目的:

审查细胞癌 (RCC) 的不断发展的治疗策略.
突出立体体辐射疗法 (SBRT) 和免疫检查点抑制剂 (ICI) 的不断扩大的作用.
讨论这些新疗法在RCC的各个阶段的整合.

主要方法:

对RCC治疗的当前文献和临床试验数据的审查.
在RCC中分析SBRT和ICI的疗效和应用.
讨论治疗序列和生物标志物的发展.

主要成果:

基于免疫检查点抑制剂 (ICI) 的双倍药物现在是高级RCC的标准前线治疗方法,显著改善了生存率.
辅助 pembrolizumab 已经证明有效性在减少RCC复发后nephrectomy.
立体体辐射疗法 (SBRT) 越来越多地用于寡头转移性或寡头渐进性RCC,通常与全身疗法相结合,包括ICI双重疗法.

结论:

对RCC的治疗模式正在转向早期使用ICI和组合疗法.
在管理本地化和先进的RCC方面,SBRT发挥着越来越重要的作用.
目前正在进行的研究重点是预测生物标志物,以个性化RCC治疗策略.

关键词:

免疫检查点抑制剂免疫检查点抑制剂免疫治疗是一种免疫疗法.脏癌症是什么? 脏癌症是什么细胞癌是细胞癌.

更多相关视频

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.